BLAZE
Research type
Research Study
Full title
A Phase I/II trial of Bexmarilimab and Nivolumab in Patients with Solid Tumours, Non-Small Cell Lung Cancer and Melanoma (BLAZE)
IRAS ID
1009285
Contact name
Anna Minchom
Contact email
Sponsor organisation
The Institute of Cancer Research
Clinicaltrials.gov Identifier
Research summary
The BLAZE study will test whether the combination of bexmarilimab and nivolumab can help patients whose cancers have stopped responding to immunotherapy treatment. It will focus on two cancers: non-small cell lung cancer and melanoma. Early research suggests bexmarilimab may change some immune cells inside the tumour so they create a stronger “attack” signal, which could help other immune cells recognise and kill cancer cells more effectively. This may make it easier for PD-1 immunotherapy drugs to work again by helping the immune system stay active against the tumour.
This is a Phase I/II clinical trial. In Phase I, researchers will give increasing doses of bexmarilimab together with a standard (fixed) dose of nivolumab to patients with solid tumours, to find the safest and most suitable dose to use going forward (the recommended Phase 2 dose). In Phase II, the study will treat two groups of patients—one with non-small cell lung cancer and one with melanoma—using that selected dose.REC name
London - Chelsea Research Ethics Committee
REC reference
26/LO/0372
Date of REC Opinion
23 Jun 2026
REC opinion
Further Information Favourable Opinion